Abstract
Pediatric kidney transplantation (KTx) offers the best outcomes for children with end-stage renal disease (ESRD), offering dramatic improvements in survival, quality of life, growth, and developmental outcomes compared to dialysis. Modern regimens centered on tacrolimus, mycophenolate mofetil, and risk-adapted induction have substantially reduced acute rejection and improved graft survival. This viewpoint summarizes the evolution of pediatric immunosuppression, current practice trends, and emerging strategies aimed at minimizing toxicity while preserving long-term graft function. Recent data show increasing use of T-cell-depleting induction, selective application of IL-2 receptor antagonists, and gradual adoption of steroid-sparing and mTOR-based protocols. Nevertheless, progress is limited by a scarcity of pediatric randomized trials, continued reliance on extrapolated adult evidence, infection risk, long-term metabolic complications, and adherence challenges during adolescence. Insights from recent trials including steroid minimization, everolimus-based regimens, and selective Belatacept use highlight opportunities for more individualized, risk-adapted therapy. Future efforts must prioritize precision approaches supported by biomarkers, multicenter collaboration, and long-term follow-up. Overall, contemporary trends support a shift toward tailored immunosuppression that balances efficacy with safety to optimize outcomes in pediatric KTx recipients.